Ichor® Medical Systems Inc., a privately-held biotech company founded in San Diego in 1994, is developing products based on the in vivo application of electroporation to enhance intracellular delivery of nucleic acid-based drugs encoding therapeutic proteins, antigens for vaccines, or antibodies for passive immunity, to treat and prevent debilitating or life threatening diseases. Ichor’s proprietary TriGrid® Delivery System was the first integrated and fully automated system for electroporation-mediated in vivo nucleic acid administration, enabling total control of the site of injection, placement of electrodes, rate of agent administration, and timing of electroporation delivery. As a result, TriGrid enables the clinical application of electroporation in a manner capable of supporting development and commercialization of nucleic acid-based products.